ETHYPHARM
PharmaETHYPHARM is a pharmaceutical company focused on Infectious Disease, Cardiovascular, Gastroenterology.
ETHYPHARM's Key Drugs
ETHYPHARM's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, spanning Infectious Disease and Cardiovascular — its most strategically important drugs approved in the last 15 years.
ETHYPHARM's Recent FDA Approvals
New NDA/BLA approvals for ETHYPHARM over the last two years — novel drugs only, excluding generics and label supplements.
ETHYPHARM's Therapeutic Areas
ETHYPHARM's approved drugs and pipeline span 4 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ETHYPHARM's Top Competitors
ETHYPHARM's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ETHYPHARM Pipeline Snapshot
ETHYPHARM has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1969-07-29
- Latest
- 2025-12-22
- Applications
- 4